The CEO's announcement of openness to partnerships for the Huntington's disease drug, coupled with significant inbound interest, indicates a proactive approach to development and commercialization. This could lead to positive market sentiment, attracting investor attention and potentially driving up the stock price in the short term. Partnerships in the biotech industry often lead to increased resources, expertise, and financial backing, which can accelerate drug development processes and enhance a company's valuation.